{
    "organizations": [],
    "uuid": "9df7550fe2296751b261ef43d331523b0e10f91c",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-alder-biopharmaceuticals-enters-in/brief-alder-biopharmaceuticals-enters-into-european-patent-settlement-global-license-agreement-with-teva-idUSFWN1P30L8",
    "ord_in_thread": 0,
    "title": "BRIEF-Alder Biopharmaceuticals Enters Into European Patent Settlement, Global License Agreement With Teva",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 8 (Reuters) - Alder Biopharmaceuticals Inc:\n* ALDER BIOPHARMACEUTICALS® ENTERS INTO EUROPEAN PATENT SETTLEMENT AND GLOBAL LICENSE AGREEMENT WITH TEVA IN THE FIELD OF ANTI-CGRP-BASED THERAPY\n* ALDER BIOPHARMACEUTICALS INC - ‍ALDER HAS AGREED TO MAKE AN IMMEDIATE ONE-TIME PAYMENT OF $25 MILLION TO TEVA​\n* ALDER BIOPHARMACEUTICALS INC - UNDER TERMS OF AGREEMENT, ALDER HAS AGREED TO WITHDRAW ITS APPEAL BEFORE EUROPEAN PATENT OFFICE\n* ALDER BIOPHARMACEUTICALS - UNDER TERMS CO AGREED TO PAY $75 MILLION AT EACH OF TWO SALES-RELATED MILESTONES FOLLOWING COMMERCIAL LAUNCH OF EPTINEZUMAB\n* ALDER SAYS UNDER TERMS CO AGREED TO PROVIDE CERTAIN ROYALTY PAYMENTS ON NET SALES AT RATES FROM 5% TO 7% FOLLOWING COMMERCIAL LAUNCH OF EPTINEZUMAB\n* ALDER - UNDER TERMS CO AGREED TO MAKE SECOND ONE-TIME PAYMENT OF $25 MILLION UPON APPROVAL OF BLA FOR EPTINEZUMAB WITH U.S. FDA Source text for Eikon: Further company coverage:\n ",
    "published": "2018-01-08T21:33:00.000+02:00",
    "crawled": "2018-01-09T16:50:59.033+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "alder",
        "biopharmaceuticals",
        "inc",
        "alder",
        "enters",
        "european",
        "patent",
        "settlement",
        "global",
        "license",
        "agreement",
        "teva",
        "field",
        "therapy",
        "alder",
        "biopharmaceuticals",
        "inc",
        "agreed",
        "make",
        "immediate",
        "payment",
        "million",
        "alder",
        "biopharmaceuticals",
        "inc",
        "term",
        "agreement",
        "alder",
        "agreed",
        "withdraw",
        "appeal",
        "european",
        "patent",
        "office",
        "alder",
        "biopharmaceuticals",
        "term",
        "co",
        "agreed",
        "pay",
        "million",
        "two",
        "milestone",
        "following",
        "commercial",
        "launch",
        "eptinezumab",
        "alder",
        "say",
        "term",
        "co",
        "agreed",
        "provide",
        "certain",
        "royalty",
        "payment",
        "net",
        "sale",
        "rate",
        "following",
        "commercial",
        "launch",
        "eptinezumab",
        "alder",
        "term",
        "co",
        "agreed",
        "make",
        "second",
        "payment",
        "million",
        "upon",
        "approval",
        "bla",
        "eptinezumab",
        "fda",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}